Literature DB >> 10954522

Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process.

H Zhang1, R J Pomerantz, G Dornadula, Y Sun.   

Abstract

Virion infectivity factor (Vif) is a protein encoded by human immunodeficiency virus types 1 and 2 (HIV-1 and -2) and simian immunodeficiency virus, plus other lentiviruses, and is essential for viral replication either in vivo or in culture for nonpermissive cells such as peripheral blood lymphoid cells, macrophages, and H9 T cells. Defects in the vif gene affect virion morphology and reverse transcription but not the expression of viral components. It has been shown that Vif colocalizes with Gag in cells and Vif binds to the NCp7 domain of Gag in vitro. However, it seems that Vif is not specifically packaged into virions. The molecular mechanism(s) for Vif remains unknown. In this report, we demonstrate that HIV-1 Vif is an RNA-binding protein and specifically binds to HIV-1 genomic RNA in vitro. Further, Vif binds to HIV-1 RNA in the cytoplasm of virus-producing cells to form a 40S mRNP complex. Coimmunoprecipitation and in vivo UV cross-linking assays indicated that Vif directly interact with HIV-1 RNA in the virus-producing cells. Vif-RNA binding could be displaced by Gag-RNA binding, suggesting that Vif protein in the mRNP complex may mediate viral RNA interaction with HIV-1 Gag precursors. Furthermore, we have demonstrated that these Vif mutants that lose the RNA binding activity in vitro do not support vif-deficient HIV-1 replication in H9 T cells, suggesting that the RNA binding capacity of Vif is important for its function. Further studies regarding Vif-RNA interaction in virus-producing cells will be important for studying the function of Vif in the HIV-1 life cycle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954522      PMCID: PMC116333          DOI: 10.1128/jvi.74.18.8252-8261.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Impact of human immunodeficiency virus type 1 RNA dimerization on viral infectivity and of stem-loop B on RNA dimerization and reverse transcription and dissociation of dimerization from packaging.

Authors:  N Shen; L Jetté; C Liang; M A Wainberg; M Laughrea
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  The double-stranded RNA-binding protein Staufen is incorporated in human immunodeficiency virus type 1: evidence for a role in genomic RNA encapsidation.

Authors:  A J Mouland; J Mercier; M Luo; L Bernier; L DesGroseillers; E A Cohen
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  A study of the dimer formation of Rous sarcoma virus RNA and of its effect on viral protein synthesis in vitro.

Authors:  E Bieth; C Gabus; J L Darlix
Journal:  Nucleic Acids Res       Date:  1990-01-11       Impact factor: 16.971

4.  Purification and visualization of native spliceosomes.

Authors:  R Reed; J Griffith; T Maniatis
Journal:  Cell       Date:  1988-06-17       Impact factor: 41.582

5.  Binding sites of viral protein P19 onto Rous sarcoma virus RNA and possible controls of viral functions.

Authors:  J L Darlix; P F Spahr
Journal:  J Mol Biol       Date:  1982-09-15       Impact factor: 5.469

6.  Tables for estimating sedimentation through linear concentration gradients of sucrose solution.

Authors:  C R McEwen
Journal:  Anal Biochem       Date:  1967-07       Impact factor: 3.365

7.  Interaction of mRNA with proteins in vesicular stomatitis virus-infected cells.

Authors:  S A Adam; Y D Choi; G Dreyfuss
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

8.  Inhibition of protein synthesis in vesicular stomatitis virus infected Chinese hamster ovary cells: role of virus mRNA-ribonucleoprotein particle.

Authors:  C A Rosen; J Siekierka; H L Ennis; P S Cohen
Journal:  Biochemistry       Date:  1984-05-22       Impact factor: 3.162

9.  Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions.

Authors:  A Lever; H Gottlinger; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

10.  Classification and purification of proteins of heterogeneous nuclear ribonucleoprotein particles by RNA-binding specificities.

Authors:  M S Swanson; G Dreyfuss
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

View more
  58 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Recent Insights into HIV Accessory Proteins.

Authors:  Jenny L. Anderson; Thomas J. Hope
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

4.  Vif is an auxiliary factor of the HIV-1 reverse transcriptase and facilitates abasic site bypass.

Authors:  Reynel Cancio; Silvio Spadari; Giovanni Maga
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

Review 5.  Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function.

Authors:  Gilles Mirambeau; Sébastien Lyonnais; Robert J Gorelick
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

Review 6.  Properties and functions of the nucleocapsid protein in virus assembly.

Authors:  Delphine Muriaux; Jean-Luc Darlix
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

7.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

8.  Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity.

Authors:  Jared R Auclair; Karin M Green; Shivender Shandilya; James E Evans; Mohan Somasundaran; Celia A Schiffer
Journal:  Proteins       Date:  2007-11-01

Review 9.  Advances in the structural understanding of Vif proteins.

Authors:  Pierre Barraud; Jean-Christophe Paillart; Roland Marquet; Carine Tisné
Journal:  Curr HIV Res       Date:  2008-03       Impact factor: 1.581

10.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.